LCMC3: adjuvant and neoadjuvant atezolizumab in early-stage NCSLC

(1:39)

LCMC3 primary analysis: Neoadjuvant atezolizumab in NSCLC

(2:59)

Advances in Immunotherapy \u0026 Resectable Non-Small Cell Lung Cancer

(45:21)

Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLC

(1:48)

Is adjuvant immunotherapy necessary in non-small cell lung cancer?

(1:52)

Adjuvant Versus Neoadjuvant Chemotherapy for NSCLC

(2:58)

Adjuvant atezolizumab in NSCLC

(1:41)

Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy

(2:31)

Adjuvant Versus Neoadjuvant Therapy in NSCLC

(3:6)

Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLC

(59)

For NSCLC Neoadjuvant Adjuvant or Both

(11:12)

Adjuvant Chemotherapy for Early Stage NSCLC Patients Part 1

(5:28)

Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial

(2:20)

Surgical perspective on neoadjuvant IO for resectable stage III NSCLC

(6:37)

Adjuvant Immunotherapy: Questions/Concerns - Leading Developments \u0026 Current Questions in Lung Cancer

(11:11)

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer

(3:2)

Practical Considerations for Adjuvant vs. Neoadjuvant Immunotherapy in NSCLC

(2:32)

IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC

(4:50)

ADAURA: osimertinib adjuvant therapy on CNS disease recurrence

(3:30)

Adjuvant chemotherapy in NSCLC patients treated with preoperative chemotherapy

(2:38)